PeterAnthonyCampochiaroMD

PubMed

• Improved protocol for histological and histopathological preparation of large eyes.
  Mingliang Zhang, Raquel Lima E Silva, Lingli Zhou, Sean F Hackett, Peter A Campochiaro
  Microscopy Research and Technique. 2024-09-05
• Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.
  Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff
  Ophthalmology. Retina. 2024-08-30
• 2 citations
  Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vis...
  Robert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu
  The British Journal of Ophthalmology. 2024-08-22

Journal Articles

• The Mechanism of Cone Cell Death in Retinitis Pigmentosa  
  Peter Campochiaro, MD, ScienceDirect
• Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for retinal vein occlusion (ORVO) study  
  Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian, Am J Ophthalmol, 1/16/2015
• Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes  
  Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Am J Ophthalmol, 1/1/2015
• Is there excess oxidative stress and damage in eyes of patients with retinitis pigmentosa?  
  Strauss RW, Lu L, Hafiz G, Wolfson Y, Shah SM, Mir T, Scholl HP, Antioxid Redox Signal, 1/1/2015
• Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab  
  Sophie R, Lu N, Ophthalmology, 1/1/2015
• Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE trial  
  Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Duh E, Ying H, Wenick A, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R, Ophthalmology, 1/1/2015
• Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A  
  Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog, JKJ, Baumann M, Shen J, Iwase T, Tian J, Stevens R, Hackett SF, Stumpp MT, Angiogenesis, 1/1/2014
•  
  Valapala M, Wilson C, Hose S, Bhutto IA, Grebe R, Dong A, Greenbaum S, Gu L, Sergeev Y, Handa JT, Wawrousek E, Zigler JS, Sinha, Autophagy, 1/1/2014
• Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature  
  Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Silva RL, Dong A, Hackett SF, Wang J, Howard BW, Vestweber D, Kontos CD, Peters KG, J Clin Invest, 1/1/2014
• Vascular disrupting agent for neovascular age-related macular degeneration: a pilot study of the safety and efficacy of for neovascular age-related macular degeneratio...  
  Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz F, Donahue JK, Rivers R, Balkissoon J, Handa JT, Nguyen QD, BMC Pharmacol Toxicol, 1/1/2013
• Ocular neovascularization  
  Campochiaro PA, J Mol Med (Berl), 1/1/2013
• Gene Consortium Seven new loci associated with age-related macular degeneration  
  Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP Jr, Buitendijk GH, Sim X, Weeks DE, Guymer RH, Merriam JE..., Nat Genet, 1/1/2013
• Sustained delivery of a HIF-1 antagonist for ocular neovascularization  
  Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima E, Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J,, J Control Release, 1/1/2013
• Ranibizumab for macular edema due to retinal vein occlusions: long term follow up in the HORIZON trial  
  Heier JS, Yau L, Li Z, Saroj N, Rubio RG, Lai P, Ophthalmology, 1/1/2012
• Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2  
  de Melo J, Miki K, Rattner A, Smallwood P, Zibetti C, Hirokawa K, Monuki ES, Blackshaw S, Proc Natl Acad Sci USA, 1/1/2012
• Anti-vascular endothelial growth factor treatment for retinal vein occlusions  
  Campochiaro PA, Ophthalmologica, 1/1/2012
• Sustained delivery fluocinolone acetonide vitreous Inserts provided benefit for at least 3 years in patients with diabetic macular edema  
  Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME S..., Ophthalmologica, 1/1/2012
• Long term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosa  
  Ohnaka M, Miki K, Gong YY, Stevens R, Iwase T, Hackett SF, J Neurochem, 1/1/2012
• Suppression of GLUT1: a new strategy to prevent diabetic complications  
  Lu L, Seidel CP, Iwase T, Stevens RK, Gong YY, Wang X, Hackett SF, J. Cell. Physiol, 1/1/2012
• Heritability and Genome-Wide Association Study to Assess Genetic Differences between Advanced Age-Related Macular Degeneration Subtypes  
  Sobrin L, Ripke S, Yu Y, Fagerness J, Bhangale TR, Tan PL, Souied EH, Buitendijk GH, Merriam JE, Richardson AJ, Raychaudhuri S, Reynolds R, Chin KA, Lee AY, Leveziel N..., Ophthalmology, 1/1/2012
• Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration  
  Nguyen QD, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, Do DV, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarb..., J Ocular Pharmacol Ther, 1/1/2012
• Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration  
  Oveson BC, Iwase T, Hackett SF, Lee SY, Usui S, Sedlak TW, Snyder SH, Sung JU, J Neurochem, 1/1/2011
• Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema  
  Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE, for the FAME Study Group, Ophthalmology, 1/1/2011
• Treatment of macular edema due to retinal vein occlusion  
  Channa R, Smith M, Clin Ophthalmol, 1/1/2011
• Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration  
  Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, Tan PL, Souied EH, Richardson AJ, Merriam JE, Buitendijk GH, Reynolds R, Raychaudhuri S, Chin KA, Sobrin L, Ev..., Hum Mol Genet, 1/1/2011
• Join now to see all

Books/Book Chapters

• Octreotide: The Next Decade 
  Chapter: Diabetic retinopathy: Current treatment and prospects for pharmacologic therapy 
  Campochiaro PAEditors: SWJ Lamberts.BioScientifica Ltd1999
• Progress in Retinal and Eye Research 
  Chapter: Growth factors in the retina and retinal pigmented epithelium 
  Page 547 - 567Hackett SF and Vinores SAEditors: N.N. Osborne and G.J. Chader.Elsevier Science Ltd, England1996
• Clinical Management of Poisoning and Drug Overdose 
  Chapter: Management of eye-related problems due to chemical and drug toxicity 
  Page 369 - 388Fogle JA and Spiker DAEditors: L.M. Haddad and J.F. Winchester.W.B. Saunders Co., PhiladelphiaEdition 2nd,1990
• Proliferative Vitreoretinopathy 
  Chapter: The role of breakdown of the blood-retinal barrier in proliferative vitreoretinopathy 
  Page 45 - 49Sen HA, Robertson TJ and Conway BPEditors: K. Heimann and P. Wiedeman.Kaden, Keidelburg1989
• Catecholamines: Basic and Clinical Frontiers, Volume 1 
  Chapter: An animal model for Huntington's Disease: striatal kainic acid lesion 
  Page 751 - 756Coyle JT, Biziere K, London ED, Schwarcz R, Zaczek DEditors: E. Usdin, I. Kopin, and J. Barchas.1979
• GABA Neurotransmitters, Alfred Benzon Symposium 12 
  Chapter: Kainic acid induced lesion of striatum as an animal model for Huntington's Disease 
  Page 419 - 431Coyle JT, Biziere K, Schwarcz R, Zaczek REditors: H. Kofod, P. Kroggsgaard-Larsen, and J. Scheel-Kruger.Munksgaard, Copenhagen1978
• Proc 10th Collegium Internationale Neuro-Psychopharmacologicum 
  Chapter: Changing Relationships among neutransmitter systems in developing striatum: implications for neuropsychopharmacology 
  Page 1363 - 1370Coyle JT, Zaczek RPergamon Press, Oxford1977
• Maturation of Biochemical NeurotransmissionMechanisms 
  Chapter: Neutoxic action of kainic acid in the developing rat striatum 
  Page 131 - 141Coyle JT, London EDKarger, Basel1977
• Join now to see all

Lectures

• Mechanism of Cone Cell Death in Retinitis Pigmentosa 
  Lecce, Italy, 2010; Cordoba, Argentina, 2010; Schepens Eye Research Institute, 2015 - 1/1/2015
• Pharmacologic Delivery with Gene Therapy 
  1/1/2014
• Treatment of Macular Edema Due to Retinal Vein Occlusions 
  Osaka, Japan - 1/1/2014
• Mechanisms of Cone Cell Death in Retinitis Pigmentosa 
  Nagoya University, Nagoya, Japan - 1/1/2014
• Pathogenesis and Treatment of Diabetic Retinopathy 
  1/1/2012
• Pathogenesis of Ocular Neovascularization 
  University of Michigan - 1/1/2011
• Gene Transfer for Ocular Neovascularization 
  Federal Drug Administration - 1/1/2011
• New Treatments for Diabetic Macular Edema and Retinal Vein Occlusions 
  Moorfields Eye Institute, London, England, 2008; University of Michigan, 2011 - 1/1/2011
• Ocular Neovascularization: Mechanisms and Prospects for New Treatments 
  University of Nebraska, Omaha, NE, 2010; The National Academy of Science and Medicine of Argentina, - 1/1/2010
• Mechanisms and Potential New Treatments for Ocular Neovascularization 
  Lecce, Italy - 1/1/2010
• Is VEGF Blockade Toxic to the Retina 
  1/1/2010
• New Treatments for Diabetic Macular Edema 
  New Jersey Medical School, Newark, NJ - 1/1/2009
• Mechanisms Involved in the Pathogenesis of Ocular Neovascularization 
  New Jersey Medical School, Newark, NJ - 1/1/2009
• New Treatments for Ocular Neovascularization and Macular Edema 
  Multiple Locations, 2007 - 1/1/2009
• Molecular Pathogenesis of Ocular Neovascularization; Similarities and Differences With Tumor Angiogenesis 
  Kyoto, Japan - 1/1/2008
• Oxidative Damage and Cone Cell Death in Retinitis Pigmentosa 
  Beijing, China, 2007; Emeishan, Sichuan, China, 2008 - 1/1/2008
• Ocular Neovascularization, A Valuable Model System 
  King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia - 1/1/2008
• New Treatments for Choroidal Neovascularization and Diabetic Macular Edema 
  King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia - 1/1/2008
• Pathogenesis of Cone Cell Death in Retinitis Pigmentosa 
  Institute of Ophthalmology, University College, London, England - 1/1/2008
• Ocular Neovascularization and Macular Edema 
  Allergan, Newport Beach, CA - 1/1/2007
• VEGF Antagonists for Retinal Vascular Diseases 
  University of Rochester Department of Ophthalmology - 1/1/2007
• Molecular Pathogenesis of Ocular Neovascularization and Macular Edema 
  University of Rochester Department of Ophthalmology - 1/1/2007
• Ocular Gene Therapy 
  Urberlandia, Brazil, 2007; Beijing, China, 2007 - 1/1/2007
• VEGF antagonists for Diabetic Macular Edema 
  Urberlandia, Brazil - 1/1/2007
• New Treatments for Ocular Neovascularization 
  University of Illinois, Chicago - 1/1/2006
• Join now to see all